The hypothalamic-pituitary-adrenal axis in borderline personality disorder: A review

Harvard Review of Psychiatry

Volumn 17, Issue 3, 2009, Pages 167-183

  Zimmerman, Daniel J ^a   Choi Kain, Lois Wonsun ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

Borderline personality disorder; Corticotropin releasing hormone; Cortisol; Dexamethasone suppression test; Hypothalamic pituitary adrenal axis; Stress

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; BIOLOGICAL MARKER; HYDROCORTISONE;

BORDERLINE STATE; CHILD ABUSE; CLINICAL ASSESSMENT; COMORBIDITY; DEPRESSION; DISSOCIATIVE DISORDER; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIMBIC SYSTEM; MEDLINE; MENTAL STRESS; NEGATIVE FEEDBACK; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ENDOCRINE FUNCTION TEST; HYPOPHYSIS ADRENAL SYSTEM; METABOLISM;

ADRENAL CORTEX FUNCTION TESTS; BIOLOGICAL MARKERS; BORDERLINE PERSONALITY DISORDER; CORTICOTROPIN-RELEASING HORMONE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; STRESS, PSYCHOLOGICAL;

EID: 69249209979     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220902996734     Document Type: Review

References (114)

1. McGlashan TH, Grilo CM, Sanislow CA, et al. Two-year prevalence and stability of individual criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. Am J Psychiatry 2005;162:833-889
2. Zanarini MC, Frankenburg FR, Reich DB, Silk KR, Hudson JI, McSweeney LB. The subsyndromal phenomenology of borderline personality disorder: A 10-year follow-up study. Am J Psychiatry 2007;164:929-935
3. Zanarini MC, Gunderson JG, Frankenburg FR, Chauncey DL. Discriminating borderline personality disorder from other Axis II disorders. Am J Psychiatry 1990;147:161-167
4. Ellison JM, Blum NR, Barsky AJ. Frequent repeaters in a psychiatric emergency service. Hosp Community Psychiatry 1989;40:958-960
5. Linehan MM, Heard HL, Armstrong HE. Naturalistic followup of a behavioral treatment for chronically parasuicidal borderline patients. Arch Gen Psychiatry 1993;50:971-974
6. Bateman A, Fonagy P. Effectiveness of partial hospitalization in the treatment of borderline personality disorder: A randomized controlled trial. Am J Psychiatry 1999;156:1563-1569
7. Bateman A, Fonagy P. Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: An 18-month follow-up. Am J Psychiatry 2001;158:36-42.
8. Blum N, Pfohl B, John DS, Monahan P, Black DW. STEPPS: A cognitive-behavioral systems-based group treatment for outpatients with borderline personality disorder-a preliminary report. Compr Psychiatry 2002;43:301-310
9. Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF. Evaluating three treatments for borderline personality disorder: A multiwave study. Am J Psychiatry 2007;164:922-928
10. Skodol AE, Gunderson JG, Pfohl B, Widiger TA, Livesley WJ, Siever LJ. The borderline diagnosis I: Psychopathology, psychopathology, comorbidity, and personality structure. Biol Psychiatry 2002;51:936-950
11. Yen S, Pagano ME, Shea MT, et al. Recent life events preceding suicide attempts in a personality disorder sample: Findings from the Collaborative Longitudinal Personality Disorders Study. J Consult Clin Psychol 2005;73:99-105.
12. Brain KL, Haines J, Williams CL. The psychophysiology of self-mutilation: Evidence of tension reduction. Arch Suicide Res 1998;4:227-242
13. Stanley B, Brodsky B. Suicidal and self-injurious behavior in borderline personality disorder: The self-regulation action model. In: Gunderson J, Hoffman P, eds. Understanding and treating borderline personality disorder. Washington, DC: American Psychiatric Press, 2005.
14. Sachsse U, Von der Heyde S, Huether G. Stress regulation and self-mutilation. Am J Psychiatry 2002;159:672.
15. Stiglmayr CE, Ebner-Priemer UW, Bretz J, et al. Dissociative symptoms are positively related to stress in borderline personality disorder. Acta Psychiatr Scand 2008;117:139-147
16. Pagano ME, Skodol AE, Stout RL, et al. Stressful life events as predictors of functioning: Findings from the Collaborative Longitudinal Personality Disorders Study. Acta Psychiatr Scand 2004;110:421-429
17. Jovev M, Jackson HJ. The relationship of borderline personality disorder, life events and functioning in an Australian psychiatric sample. J Pers Disord 2006;20:205-217
18. Linehan MM, Heard HL, Armstrong HE. Naturalistic followup of a behavioral treatment for chronically parasuicidal borderline patients. Arch Gen Psychiatry 1993;50:971-974
19. Carroll BJ, Martin FI, Davies B. Pituitary-adrenal function in depression. Lancet 1968;1:1373-1374
20. Carroll BJ, Feinberg M, Greden JF, et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 1981;38:15-22.
21. Arana GW, Baldessarini JR, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Arch Gen Psychiatry 1985;42:1193-1204
22. Ribeiro SC, Tandon R, Grunhaus L, Greden JF. The DST as a predictor of outcome in depression: A meta-analysis. Am J Psychiatry 1993;150:1618-1629
23. Yehuda R, Southwick SM, Nussbaum G, Wahby V, Giller EL Jr, Mason JW. Low urinary cortisol excretion in patients with posttraumatic stress disorder. J NervMent Dis 1990;178:366-369
24. Yehuda R. Advances in understanding neuroendocrine alteration in PTSD and their therapeutic implications. Ann N Y Acad Sci 2006;1071:137-166
25. Nemeroff CB. Neurobiological consequences of childhood trauma. J Clin Psychiatry 2004;65 suppl 1:18-28.
26. Claes SJ. Corticotropin-releasing hormone (CRH) in psychiatry: From stress to psychopathology. Ann Med 2004;36:50-61.
27. Pfennig A,Kunzel HE,KernN, et al. Hypothalamus-pituitaryadrenal system regulation and suicidal behavior in depression. Biol Psychiatry 2005;57:336-342
28. Jokinen J, Carlborg A, M°artensson B, Forslund K, Nordstr̈om AL, Nordstr̈om P. DST non-suppression predicts suicide after attempted suicide. Psychiatry Res 2007;150:297-303.
29. Kendler KS, Karkowski LM, Prescott CA. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999;156:837-841
30. Caspi A, Sudgen K, Moffitt TE, et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-389
31. Sanchez MM, Ladd CO, Plotsky PM. Early adverse experience as a developmental risk factor for later psychopathology: Evidence from rodent and primate models. Dev Psychopathol 2001;13:419-449
32. McEwen BS. Influences of the adrenocortical hormones on pituitary and brain function. Monogr Endocrinol 1979;12:467-492
33. De Kloet CS, Vermetten E, Geuze E, Kavelaars A, Heinknen CJ, Westenberg HGM. Assessment of HPA-axis function in posttraumatic stress disorder: Pharmacological and nonpharmacological challenge tests, a review. J Psychiatr Res 2006;40:550-567
34. Clinton S, Miller S, Watson SJ, Akil H. Prenatal stress does not alter innate novelty-seeking behavioral traits, but differentially affects individual differences in neuroendocrine stress responsivity. Psychoneuroendocrinology 2008;33:162-177
35. Macri S, Spinelli S, Adriani W, Dee Higley J, Laviola G. Early adversity and alcohol availability persistently modify serotonin and hypothalamic- pituitary-adrenal-axis metabolism and related behavior: What experimental research on rodents and primates can tell us. Neurosci Biobehav Rev 2007;31:172-180
36. McCormick CM, Smith C, Mathews IZ. Effects of chronic social stress in adolescence on anxiety and neuroendocrine response to mild stress in male and female rats. Behav Brain Res 2008;187:228-238
37. Perez-Laso C, Segovia S, Martin JL, Ortega E, Gomez F, Del Cerro MC. Environmental prenatal stress alters sexual dimorphism of maternal behavior in rats. Behav Brain Res 2008;187:284-288
38. Heim C, Nemeroff CB.Neurobiology of early life stress: Clinical studies. Semin Clin Neuropsychiatry 2002;7:147-159
39. Stone MH. Long-term outcome in personality disorders. Br J Psychiatry 1993;162:299-313.
40. McGlashan TH. The Chestnut Lodge follow-up study. III. Long-term outcome of borderline personalities. Arch Gen Psychiatry 1986;43:20-30.
41. Zanarini MC, Gunderson JG, Frankenburg FR. Axis I phenomenology of borderline personality disorder. Compr Psychiatry 1989;30:149-156
42. Zanarini MC, Williams AA, Lewis RE, et al. Reported pathological childhood experiences associated with the development of borderline personality disorder. Am J Psychiatry 1997;154:1101-1106
43. Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry 1998;155:1733-1739
44. Zimmerman M, Mattia JI. Axis I diagnostic comorbidity and borderline personality disorder. Compr Psychiatry 1999;40:245-252
45. Skodol AE, Oldham JM, Gallaher PE. Axis II comorbidity of substance use disorders among patients referred for treatment of personality disorders. Am J Psychiatry 1999;156:733-738
46. Frankenburg FR, Zanarini MC. The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. J Clin Psychiatry 2004;65:1660-1665
47. McEwen, BS. Corticosteroids and hippocampal plasticity. Ann N Y Acad Sci 1994;746:134-142
48. Sapolsky RM. Stress and plasticity in the limbic system. Neurochem Res 2003;28:1735-1742
49. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotrophin-releasing factor administration: Is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 1990;15:71-100.
50. Bale TL, Contarino A, Smith GW, et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxietylike behaviour and are hypersensitive to stress. Nat Genet 2000;24:410-414
51. Nemeroff CB, Vale WW. The neurobiology of depression: Inroads to treatment and new drug discovery. J Clin Psychiatry 2005;66 suppl 7:5-13.
52. Packan DR, Sapolsky RM. Glucocorticoid endangerment of the hippocampus: Tissue, steroid and receptor specificity.Neuroendocrinology 1990;51:613-618
53. Bremner JD. Does stress damage the brain? Biol Psychiatry 1999;45:797-805.
54. Sonino N, Fava GA. Psychosomatic aspects of Cushing's disease. Psychother Psychosom 1998;67:140-146
55. Musselman DL, Nemeroff CB. Depression and endocrine disorders: Focus on the thyroid and adrenal system. Br J Psych Suppl 1996;30:123-128
56. Herman JP, Ostrander MM, Mueller NK, Figueiredo H. Limbic system mechanisms of stress regulation: Hypothalamopituitary- adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1201-1213
57. Val E, Nasr SJ, FilogonioMG, Prasad RB [Letter to the editor]. Am J Psychiatry 1983;140:6.
58. Ferrari M, Mantero F. Male aging and hormones: The adrenal cortex. J Endocrinol Invest 2005;28(11 suppl proceedings):92-95
59. Kirschbaum C, Kudielka BM, Gaab J, Schommer NC, Hellhammer DH. Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamuspituitary- adrenal axis. Psychosom Med 1999;61:154-162
60. Rohleder N, Kirschbaum C. Effects of nutrition on neuroendocrine stress responses. Curr Opin Clin Nutr Metab Care 2007;10:504-510
61. Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinol Metab Clin North Am 2003;32:895-914.
62. Buckley TM, Schatzberg AS. On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: Normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab 2005;90:3106-3114
63. Rinne T, de Kloet ER,Wouters L, Goekoop JG, DeRijk RH, van den BrinkW. Hyperresponsiveness of hypothalamic-pituitaryadrenal axis to combined dexamethasone/corticotropinreleasing hormone challenge in female borderline personality disorder subjects with a history of sustained child abuse. Biol Psychiatry 2002;52:1102-1112
64. Lange W, Wulff H, Berea C, et al. Dexamethasone suppression test in borderline personality disorder-effects of posttraumatic stress disorder. Psychoendocrinology 2005;30:919-923
65. Simeon D, Knutelska M, Smith L, Baker BR, Hollander E. A preliminary study of cortisol and norepinephrine reactivity to psychosocial stress in borderline personality disorder with high and low dissociation. Psychiatry Res 2007;149:177-184
66. Lieb K, Rexhausen JE, Kahl KG, et al. Increased diurnal salivary cortisol in women with borderline personality disorder. J Psychiatr Res 2004;38:559-565
67. Carrasco JL, Diaz-Marsa M, Pastrana JI, et al. Hypothalamicpituitary- adrenal axis response in borderline personality disorder without post-traumatic features. Br J Psychiatry 2007;190:357-358
68. Southwick SM, Axelrod SR, Wang S, et al. Twenty-fourhour urine cortisol in combat veterans with PTSD and comorbid borderline personality disorder. J Nerv Ment Dis 2003;191:261-262
69. Stokes PE, Sikes CR. Hypothalamic-pituitary-adrenal axis in psychiatric disorders. Annu Rev Med 1991;42:519-531
70. APA Task Force on Laboratory Tests in Psychiatry. The dexamethasone suppression test: An overview of its current status in psychiatry. Am J Psychiatry 1987;144:1253-1262
71. Gillespie CF,Nemeroff CB. Hypercortisolemia and depression. Psychosom Med 2005;67 suppl 1:S26-8.
72. Keller PA, McCluskey A, Morgan J, O'Connor SM. The role of the HPA axis in psychiatric disorders and CRF antagonists as potential treatments. Arch Pharm (Weinheim) 2006;339:346-355
73. Carroll BJ, Greden JF, Feinberg M, et al.Neuroendocrine evaluation of depression in borderline patients. Psychiatr Clin North Am 1981;4:89-99.
74. Sternbach HA, Fleming J, Extein I, Pottash AL, Gold MS. The dexamethasone suppression and thyrotropin-releasing hormone tests in depressed borderline patients. Psychoneuroendocrinology 1983;8:459-462
75. Steiner M, Martin S, Wallace JE, Goldman S. Distinguishing subtypes within the borderline domain: A combined neuroendocrine approach. Biol Psychiatry 1984;19:907-911
76. Baxter L, EdellW, Gerner R, Fairbanks L, Gwirtsman H. Dexamethasone suppression test and Axis I diagnoses of inpatients with DSM-III borderline personality disorder. J Clin Psychiatry 1984;45:150-153
77. Beeber AR, Kline MD, Pies RW, Manring JM Jr. Dexamethasone suppression test in hospitalized depressed patients with borderline personality disorder. J Nerv Ment Dis 1984;172:301-303
78. Soloff PH, George A, Nathan RS. The dexamethasone suppression test in patients with borderline personality disorders. Am J Psychiatry 1982;139:1621-1623
79. Krishnan KR, Davidson JR, Rayasam K, Shope F. The dexamethasone suppression test in borderline personality disorder. Biol Psychiatry 1984;19:1149-1153
80. Lahmeyer HW, Val E, Gaviria M, et al. EEG sleep, lithium transport, dexamethasone suppression, and monoamine oxidase activity in borderline personality disorder. Psychiatry Res 1988;25:19-30.
81. Korzekwa M, SteinerM, Links P, Eppel A. The dexamethasone suppression test in borderlines: Is it useful? Can J Psychiatry 1991;36:26-28
82. De la Fuente JM, Mendlewicz J. TRH stimulation and dexamethasone suppression in borderline personality disorder. Biol Psychiatry 1996;40:412-418
83. Kontaxakis V, Markianos M, Vaslamatzis G, Markidis M, Kanellos P, Stefanis C. Multiple neuroendocrinological responses in borderline personality disorder patients. Acta Psychiatr Scand 1987;76:593-597
84. McGlashan TH, Grilo CM, Skodol AE, et al. The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic co-occurrence. Acta Psychiatr Scand 2000;102:256-264
85. Herman JL. Trauma and recovery. New York: Basic, 1992.
86. Gunderson JG, Sabo AN. The phenomenological and conceptual interface between borderline personality disorder and PTSD. Am J Psychiatry 1993;150:19-27.
87. Rasmusson AM, Vythilingam M, Morgan CA. The neuroendocrinology of posttraumatic stress disorder: New directions. CNS Spectr 2003;8:651-6, 665-667
88. Grossman R, Yehuda R, New A, et al. Dexamethasone suppression test findings in subjects with personality disoders: Associations with posttraumatic stress disorder and major depression. Am J Psychiatry 2003;160:1291-1298
89. Wingenfeld K, LangeW,Wulff H, et al. Stability of the dexamethasone suppression test in borderline personality disorder with and without comorbid PTSD: A one-year follow-up study. J Clin Psychol 2007;63:843-850
90. Wingenfeld K, Hill A, Adam B, Driessen M. Dexamethasone suppression test in borderline personality disorder: Impact of PTSD symptoms. Psychiatry Clin Neurosci 2007;61: 681-683
91. Heuser I, Yassouridis A, Holsboer F. The combined dexamethsone/ CRH test: A refined laboratory test for psychiatric disorders. J Psychiatr Res 1994;28:341-356
92. Muhtz C, Wester M, Yassouridis A, Wiedemann K, Kellner M.Acombined dexamethsone/corticotropin releasing hormone test in patients with chronic PTSD-first preliminary results. Journal of Psychiatr Res 2008;42:689-693
93. Kirschbaum C, Pirke KM, Hellhammer DH. The Trier Social Stress Test: A tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 1993;28:1186-1197
94. Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR. Prediction of the 10-year course of borderline personality disorder. Am J Psychiatry 2006;163:827-832
95. Lahmeyer HW, Reynolds (III) CF, Kupfer DJ, King R. Biologic markers in borderline personality disorder. J Clin Psychiatry 1989;50:217-225
96. Schmahl C, Bremner JD. Neuroimaging in borderline personality disorder. J Psychiatr Res 2006;40:419-427
97. Juengling FD, Schmahl C, Hesslinger B, et al. Positron emission tomography in female patients with borderline personality disorder. J Psychiatr Res 2003;37:109-115 (Pubitemid 36808473)
98. Herbert J, Goodyer IM, Grossman AB, et al. Do corticosteroids damage the brain? J Neuroendocrinol 2006;18:393-411.
99. Fertuck EA, LenzenwegerMF, Clarkin JF, Hoermann S, Stanley B. Executive neurocognition, memory systems, and borderline personality disorder. Clin Psychol Rev 2006;26:346-375
100. Seckl JR, Meaney MJ. Glucocorticoid programming. Ann N Y Acad Sci 2004;1032:63-84.
101. Arato M, Banki CM, Bissette G, Nemeroff CB. Elevated CSF CRF in suicide victims. Biol Psychiatry 1989;25:355-359
102. Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: Preclinical and clinical studies. Biol Psychiatry 2001;49:1023-1039
103. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991;43:425-473
104. Habib KE, Weld KP, Rice KC, et al. Oral administration of a corticotropin-releasing hormone receptor antagonist signifi- cantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci U S A 2000;97:6079-6084
105. French JA, Fite JE, Jensen H, et al. Treatment with CRH-1 antagonist antalarmin reduces behavioral and endocrine responses to social stressors in marmosets (Callithrix kuhlii). Am J Primatol 2007;69:877-889
106. Zobel AW, Nickel T, K̈unzel HE, et al. Effects of the highaffinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J Psychiatr Res 2000;34:171-181
107. Suomi SJ. Early stress and adult emotional reactivity in rhesus monkeys. Ciba Found Symp 1991;156:171-183
108. Brady LS, Gold P, Herkenham M, Lynn A, Whitfeld HJ. The antidepressants fluoxetine, idazoxan, and phenelzine alter corticotrophin releasing hormone, tyrosine hydroxylase mRNA levels in rat brain: Therapeutic implications. Brain Res 1992;572:117-125
109. Brady LS, Whitfeld HJ, Fox RJ, Gold PW, Herkenham M. Long-term antidepressant administration alters corticotrophin- releasing hormone, tyrosine hydroxylase and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 1991;87:831-837
110. Veith RC, Lewis N, Langohr JL, et al. Effect of desipramine on cerebrospinal fluid concentrations of corticotrophin-releasing factor in human subjects. Psychiatry Res 1993;46:1-8.
111. Michelson D, Galliven E, Hill L, Demitrack M, Chrousis G, Gold P. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. J Clin Endrocrinol Metab 1997;82:2601-2606
112. Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A 2003;100:14293-14296
113. Gillespie CF, Nemeroff CB. Corticotropin-releasing factor and the psychobiology of early-life stress. Curr Dir Psychol Sci 2007;16:85-89
114. Gunderson JG, Stout RL, Sanislow SA, et al. New episodes and new onsets of major depression in borderline and other personality disorders. J Affect Disord 2008;111:40-45